



mRNA specialist eTheRNA has been selected as a candidate for the M&A Award Life Sciences 2022

Niel, Belgium, November 10, 2022 - eTheRNA, a leading mRNA technology company, announces its nomination for the Belgian M&A Awards 2022 in the "Best Venture Capital Deal - Life Sciences 2022" category. The nomination of eTheRNA is based on its successful Series B financing in August 2022, in which eTheRNA raised €39 million of fresh capital from reputable investors.

Bernard Sagaert, interim CEO eTheRNA, comments: "It is an honor to be nominated for this highly respected award within the Belgian economic community. Our nomination is in recognition of last summer's successful funding round, which allows us to further invest in our technology platform for mRNA and customized lipid nanoparticles (cLNPs)."

The [M&A Awards Belgium 2022](#) will be presented on 24 November 2022 at Maison de la Poste in Brussels. For the fifth year in a row, the organization is scrutinizing transactions from the period 1 October - 30 September, in this case the period 1 October 2021 - 30 September 2022. Candidates are nominated by the Belgian M&A community (advisers, law firms, corporate finance institutions, etc.). From there, a shortlist is drawn up in six categories: Best Large Cap Corporate Deal, Best Mid Cap Corporate Deal, Best Large Cap Private Equity Deal, Best Mid Cap Private Equity Deal, Best Venture Capital Deal - Technology and Best Venture Capital Deal - Life Sciences. A six-member [jury](#) evaluates all deals in detail during the jury deliberations, after which the [nominees](#) for each category are announced.

Bernard Sagaert continues: "It is gratifying to note that we are in the list of three nominees for our category alongside Precirix and Syndesi Therapeutics, two other promising companies from Belgium's successful biotech/medtech ecosystem, which are pursuing an international strategy. The international and innovative mission of eTheRNA is also underlined by the composition of our shareholder base, which since the Series B funding round also includes Novalis LifeSciences LLC and Dr Kenneth Chien, the co-founder of Moderna."

About eTheRNA

eTheRNA is an mRNA technology platform company with integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and manufacturing customized lipid nanoparticles (cLNP) formulations tailored for the prevention and treatment of various pathological states, providing end-to-end solutions for next generation mRNA therapeutics. The company believes that customized LNPs are critical enablers in advancing mRNA technologies to new levels of prophylactic and therapeutic utility.

www.etherna.be